BRAF V600E mutation does not predict recurrence after long-term follow-up in TNM stage I or II papillary thyroid carcinoma patients. (Q54314073)

27 May 2018

title

BRAF V600E mutation does not predict recurrence after long-term follow-up in TNM stage I or II papillary thyroid carcinoma patients. (English)

1 reference

27 May 2018

main subject

papillary thyroid cancer

1 reference

3

Johanna Arola

1 reference

27 May 2018

Camilla Schalin-Jäntti

2

object named as

Camilla Schalin-Jäntti

1 reference

27 May 2018

author name string

Hanna Pelttari

1

1 reference

27 May 2018

Eliisa Löyttyniemi

4

1 reference

27 May 2018

Sakari Knuutila

5

1 reference

27 May 2018

Matti J Välimäki

6

1 reference

27 May 2018

publication date

25 November 2011

1 reference

27 May 2018

Acta Pathologica et Microbiologica Scandinavica

published in

1 reference

27 May 2018

volume

120

1 reference

27 May 2018

issue

5

1 reference

27 May 2018

page(s)

380-386

1 reference

27 May 2018

Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02844.X

Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02844.X

European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02844.X

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02844.X

BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02844.X

BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02844.X

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02844.X

Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02844.X

BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02844.X

BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02844.X

BRAF mutations in an Italian cohort of thyroid cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02844.X

No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02844.X

BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02844.X

The prevalence and prognostic value of BRAF mutation in thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02844.X

Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02844.X

Long-term outcome of 495 TNM stage I or II patients with differentiated thyroid carcinoma followed up with neck ultrasonography and thyroglobulin measurements on T4 treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02844.X

Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02844.X

Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02844.X

Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02844.X

BRAF in primary and recurrent papillary thyroid cancers: the relationship with (131)I and 2-[(18)F]fluoro-2-deoxy-D-glucose uptake ability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02844.X

Higher rate of BRAF mutation in papillary thyroid cancer over time: a single-institution study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02844.X

Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02844.X

The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02844.X

The BRAFV600E mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02844.X

10.1111/J.1600-0463.2011.02844.X

21 January 2018

Identifiers

DOI

1 reference

27 May 2018

PubMed ID

22515292

1 reference

27 May 2018